vs
Side-by-side financial comparison of ASSURED GUARANTY LTD (AGO) and IDEAYA Biosciences, Inc. (IDYA). Click either name above to swap in a different company.
ASSURED GUARANTY LTD is the larger business by last-quarter revenue ($277.0M vs $207.8M, roughly 1.3× IDEAYA Biosciences, Inc.). IDEAYA Biosciences, Inc. runs the higher net margin — 57.4% vs 43.0%, a 14.4% gap on every dollar of revenue.
Assured Investment Management (AIM) was an institutional asset management firm with a heritage in credit strategies, managing approximately $15.2 billion as of its defunct status in July 2023. Secondaries Investors referred to AIM as "one of the world's most prominent hedge funds".
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
AGO vs IDYA — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $277.0M | $207.8M |
| Net Profit | $119.0M | $119.2M |
| Gross Margin | — | — |
| Operating Margin | 59.6% | 52.2% |
| Net Margin | 43.0% | 57.4% |
| Revenue YoY | 77.6% | — |
| Net Profit YoY | 561.1% | 330.1% |
| EPS (diluted) | $2.56 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $277.0M | — | ||
| Q3 25 | $207.0M | $207.8M | ||
| Q2 25 | $281.0M | — | ||
| Q1 25 | $345.0M | — | ||
| Q4 24 | $156.0M | — | ||
| Q3 24 | $269.0M | $0 | ||
| Q2 24 | $202.0M | $0 | ||
| Q1 24 | $245.0M | $0 |
| Q4 25 | $119.0M | — | ||
| Q3 25 | $105.0M | $119.2M | ||
| Q2 25 | $103.0M | — | ||
| Q1 25 | $176.0M | — | ||
| Q4 24 | $18.0M | — | ||
| Q3 24 | $171.0M | $-51.8M | ||
| Q2 24 | $78.0M | $-52.8M | ||
| Q1 24 | $109.0M | $-39.6M |
| Q4 25 | 59.6% | — | ||
| Q3 25 | 65.2% | 52.2% | ||
| Q2 25 | 47.3% | — | ||
| Q1 25 | 66.4% | — | ||
| Q4 24 | 19.2% | — | ||
| Q3 24 | 81.8% | — | ||
| Q2 24 | 46.5% | — | ||
| Q1 24 | 58.8% | — |
| Q4 25 | 43.0% | — | ||
| Q3 25 | 50.7% | 57.4% | ||
| Q2 25 | 36.7% | — | ||
| Q1 25 | 51.0% | — | ||
| Q4 24 | 11.5% | — | ||
| Q3 24 | 63.6% | — | ||
| Q2 24 | 38.6% | — | ||
| Q1 24 | 44.5% | — |
| Q4 25 | $2.56 | — | ||
| Q3 25 | $2.18 | $1.33 | ||
| Q2 25 | $2.08 | — | ||
| Q1 25 | $3.44 | — | ||
| Q4 24 | $0.40 | — | ||
| Q3 24 | $3.17 | $-0.60 | ||
| Q2 24 | $1.41 | $-0.68 | ||
| Q1 24 | $1.89 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $903.0M | $786.9M |
| Total DebtLower is stronger | $1.7B | — |
| Stockholders' EquityBook value | $5.7B | $1.1B |
| Total Assets | $12.2B | $1.2B |
| Debt / EquityLower = less leverage | 0.30× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $903.0M | — | ||
| Q3 25 | $1.3B | $786.9M | ||
| Q2 25 | $939.0M | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $1.5B | $920.0M | ||
| Q2 24 | $1.7B | $701.7M | ||
| Q1 24 | $1.6B | $698.8M |
| Q4 25 | $1.7B | — | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.7B | — | ||
| Q4 24 | $1.7B | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $1.7B | — | ||
| Q1 24 | $1.7B | — |
| Q4 25 | $5.7B | — | ||
| Q3 25 | $5.7B | $1.1B | ||
| Q2 25 | $5.6B | — | ||
| Q1 25 | $5.6B | — | ||
| Q4 24 | $5.5B | — | ||
| Q3 24 | $5.7B | $1.2B | ||
| Q2 24 | $5.5B | $931.7M | ||
| Q1 24 | $5.6B | $935.3M |
| Q4 25 | $12.2B | — | ||
| Q3 25 | $12.1B | $1.2B | ||
| Q2 25 | $12.1B | — | ||
| Q1 25 | $11.9B | — | ||
| Q4 24 | $11.9B | — | ||
| Q3 24 | $12.3B | $1.2B | ||
| Q2 24 | $12.1B | $973.7M | ||
| Q1 24 | $12.2B | $961.5M |
| Q4 25 | 0.30× | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | 0.30× | — | ||
| Q1 25 | 0.30× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.30× | — | ||
| Q2 24 | 0.31× | — | ||
| Q1 24 | 0.30× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $259.0M | $142.2M |
| Free Cash FlowOCF − Capex | — | $142.2M |
| FCF MarginFCF / Revenue | — | 68.4% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 2.18× | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | $13.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $259.0M | — | ||
| Q3 25 | $55.0M | $142.2M | ||
| Q2 25 | $78.0M | — | ||
| Q1 25 | $87.0M | — | ||
| Q4 24 | $47.0M | — | ||
| Q3 24 | $17.0M | $-49.2M | ||
| Q2 24 | $58.0M | $-32.9M | ||
| Q1 24 | $-74.0M | $-43.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | $142.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-49.7M | ||
| Q2 24 | — | $-33.9M | ||
| Q1 24 | — | $-45.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | 68.4% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 2.18× | — | ||
| Q3 25 | 0.52× | 1.19× | ||
| Q2 25 | 0.76× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 2.61× | — | ||
| Q3 24 | 0.10× | — | ||
| Q2 24 | 0.74× | — | ||
| Q1 24 | -0.68× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AGO
| Insurance Segment | $226.0M | 82% |
| Other | $37.0M | 13% |
| Gain Loss On Investments Member1 | $8.0M | 3% |
| Non Credit Impairment Related Unrealized Fair Value Gains Losses On Credit Derivatives | $6.0M | 2% |
IDYA
Segment breakdown not available.
